Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Thought Leadership
Latest Report
Vantage Pharma, Biotech and Medtech 2018 in Review
Biopharma in 2018: Year of contrasts as stocks and M&A slump, but venture financing and IPOs remain strong The Vantage 2018 in Review paints a mixed picture for biopharma and medtech in 2018. Key indicators on share price and dealmaking showed weakness, but there are signs of health from the industry in IPO outcomes, venture financing…
Report library
Vantage 2019 Preview
2019 expected to be volatile year for pharma and biotech industries The Vantage 2019 Preview looks at the risks and opportunities for the year ahead. Report…
First-line lung cancer: can Keytruda be stopped?
Only one near-term event remains to determine whether Keytruda will face any kind of challenge in first-line NSCLC. 2018 started with the promise of a first-line lung…
EvaluateMedTech World Preview 2018, Outlook to 2024
Report Highlights Worldwide medtech sales forecast to reach $595 billion by 2024, with a CAGR of 5.6%, anchored by familiar players Neurology set to be the…
EvaluatePharma ワールドプレビュー 2018、2024年への展望 日本語版
分析ハイライト 全世界の処方箋薬売上の年平均成長率は6. 4% (2018-2024年CAGR)で、2024年には1兆2,000億ドルに達すると予測 2024年の処方箋薬売上に占める研究開発費の割合は16.9% オンコロジー領域は年平均12% …
Vantage Pharma, Biotech & Medtech Half-Year Review 2018
Report Highlights Big biotech and big pharma stocks were largely shunned by investors over the first half of the year Demand for new biotech issues shows no sign of…
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.